Injection paradigm for administration of botulinum toxins
AssigneeAllergan, Inc.
InventorsCatherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
Life of this patent
Estimating the term…
Abstract
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
Claims30
1-7. (canceled)
A method for the prophylaxis of a headache in a patient with migraine headaches, the method comprising administering a composition comprising a botulinum neurotoxin to the patient by local injection at no more than 39 injection sites, thereby reducing the frequency of occurrence of headaches in the patient.
A composition comprising a lyophilized botulinum neurotoxin and albumin for use in reducing the frequency of occurrence of a headache in a patient with migraine headaches.
A method for treating or reducing the occurrence of a symptom of a medication overuse headache disorder in a patient with a medication overuse headache disorder, the method comprising administering a botulinum neurotoxin to one or more muscles of the patient by local injection at 31 to 39 injection sites, thereby treating or reducing the occurrence of the symptom of the medication overuse headache disorder in the patient.
A composition comprising a lyophilized botulinum neurotoxin and albumin for use in reducing the occurrence of a symptom of a medication overuse headache disorder in a patient with a medication overuse headache disorder.
A method for decreasing depression in a patient having depression, the method comprising administering a botulinum neurotoxin to one or more of the frontalis, corrugator, procerus, occipitalis, temporalis, trapezius, and cervical paraspinal muscles of the patient by local injection;
- wherein the depression is decreased in the patient.
A composition comprising a botulinum neurotoxin and albumin for use in decreasing depression in a patient having depression.
Dependencies are inferred from the claim text.